Halozyme Therapeutics Incorporated (HALO)

… not to mention that Alteogen has had a greater than 40% drop from its all-time high.

It’s not impossible but we have to live long enough to see it. The cash the company is generating gives it major power to do a lot of things moving forward so how effectively the money is spent will dictate how high we go. To me it looks like drug delivery for the foreseeable future is going to be controlled by Halozyme. I have zero concern with Alteogen making a dent in Halos business. My bigger concern is life after Helen if the company stays independent. At a minimum will be a faster ride from here to 350 than 3 to 82 if things go the way I would hope.

I consider our comp going forward west pharma.

Love it.. Thanks for story.. I recall the Jonathan Lim and Randall Kirk days well. I recall clinical data, made Kirk a billionaire, he has struggled since (as a billionaire struggles). Question, do you think we have 4x left to run? We’re up 25x, I want a 100 banger..

I followed Randal Kirk at the time. His 13d for 10 percent holdings popped up on my screener so I took a shot. He had bought out clinical data a couple years prior and I had a pretty big stake in that. Sold that one at 9x so figured he knew what he was doing. Had I held out 6 more years on that one would have made 27-30x. So this time I figured I’m not selling until he does. He dumped at 17 to save what’s now Pgen at the time but I liked Helen and decided to stick around. Glad I did!!! Very confident in the team now and they are ramping up for a large growth spurt so buckle up.

Ps, 50 day jumped over 200 today, it’s been a minute…

So great. I’ve got you by .15 I believe. I’m at $3, and 20 years. I remember, as I left Silicon Valley in 2006. Congratulations. So great to hear of another person who’s spent a very long term me here. Maybe we’ll have a Halo party in in st Martin if this can get to $200. Thanks for letting me know. It’s been an incredible, if not long and bumpy, journey. Still more adventure left. I got in due to Baxter deal. My dad was Baxter guy, so out of curiosity I placed a huge bet (for me), and been on ride since.

Using a discounted cash flow analysis, and a model with halo growing 15% from 2029-2035, halo is probably worth $260.

I’ve been here for 21 years at a cost of 3.15 per share. All I can say is that the yearly ROI is 300 percent on an earnings basis. At some
Point the stock is going way higher. This company is generating huge Cash and Helen knows how to invest it. All the worrying is not worth it. It’s easy to look at the stocks that are great using hindsight. Start looking for the next huge winner.

Earnings are the most important determinant. At a forward PE of less than 9 (see link below) and a PEG ratio of under 0.5, halo is still severely undervalued.
Longterm, fundamentals always win.
https://finviz.com/stock?t=HALO&p=d

You are comparing Halozyme to some of the best individual names of all time. It is easy to say that you should have invested in NVDA or apple in retrospect. 
But that’s not a realistic benchmark. For every NVDA or apple, there have been tens if not hundreds of individual names that were promising but ended up not doing well or even went belly up. 
The true benchmark is S&P 500 or Nasdaq. Compared to those, halozyme has done well since it went public. 

11.5 b enterprise is fairly rich.

I like to consider this as a west Pharma equivalent??

We’re fairly valued here, maybe overvalued. What does the future entail????

I’m
Not a technical trader, but our 59 day just crossed our 200 day today, we have a triple top, And our all time high is 82. That’s a lot unpack. Our market cap is 9.5, debt 2b - so enterprise value is 11.5b. Rev 1.8, forward p/e is 9. It’s a lot to unpack….

For a point of reference- I have friends that were with Apple and Broadcom, and Nvidia (and AMD) and many more, and they’ve made 50x - 100/200x their money. In 7 yrs. I’ve been with Halo (as a retail investor) for 20 yrs. My frustration at times was 1. I missed the 200x train while faithful to Halozyme and the thesis - even though I was so close to the action. 2. If this could be 4 banger from here, I’d like to here the thesis (ps / hint - I heard it today)

So have yours, yours with usually good info. Thanks…

No, definitely not you. You’re posts have been balanced.

PS, when I mentioned an and p at 23x, I was referencing the ootentisl upside, if management can convince street 2028- and beyond is looking good. The CFO hiring told me more than anything on that front. Doubt he’d take job if there wasn’t a pretty bright outlook!!!

Not sure if you me a bear, if so, you’ve got one wrong. I’ve been in since 2006, added in 2010. Those are my only trades. I’ve been frustrated for sure, since I work in tech and should have reallocated some to Nvidia and honestly Apple in 2007, when sat though the greatest Preso I’ve ever seen by founder of juniper who said Apple was at the center of a upcoming monster technology run. But I’ve never sold a share, nor do I plan too.

Seeing a lot more commercials for Keytruda qlex - which is sort of interesting…. Not sure what to make of it.

The S&P 500 forward P/E is bouncing between 20x and 23x

Please share

It is obvious from all the patent filings for drugs, and fancy new injectors they are setting Halozyme to produce a number of internal Drug-concentration-enhanze/AI combos......Do doubt about it.....could easily make a list of few......On the way to $100 and beyond. AR

They did that to prevent being sued. They eliminated the COO position all together. Pretty obvious that things weren’t working out.

I see chase coffman is president, hypercon - so that’s why they delineated like they did.

Interesting as well that the position is ‘President, drug delivery’ (and not just President’. it almost infers that there will be a different/new division at some point? I curious to know what that could be..

Coo was there for a very short time after promotion. No nice goodbyes or anything to say re departure so I say this wasn’t a mutual departure but a “termination” of employment. Probably a good part of the reason for the Ramsey deal. They need a different group to get them to the next level. Just shows you that Helen is on top of things and not afraid to upgrade.

Me thinks the corporate chain of command is being restructured…the CC may give a hint?…imao…r

We’ll likely be able to infer more if the replacement the coo position. So either. 1. The President hiring will be mostly offset with coo cost reductions or 2. There was a difference in opinion on direction or execution with the person in that position.

Did DR just hang a fresh scalp on his office wall with the announcement after the bell of the departure of the COO appointed on 10/1/25?…r

Hiring the President position was a Major Major investment. Helen has always been very straightforward, transparent, and conservatively bias, it’s hard for me to read this move as anything but powerfully bullish. You never know - but that is my read.

There is a good chance they will

One wonders whether there is a revision on revs/eps forthcoming prior to the earnings report?...r

The 50 day should break through the 200 today, or butt right into it. So there are technical stock price things converging right now too. Let’s hope volume stays high, even spikes higher hopefully..

Argx is breaking out in spite of the market getting weaker. My guess is that halo will follow and also break out in the next week or so.

Curious to see if he hit a new all-time high before or after earnings in early August

Another article about ARGX growth and upcoming 3rd qtr catalyst by IBD... https://www.investors.com/research/ibd-stock-of-the-day/biotech-stock-argenx-stock-wells-fargo-vyvgart-sales-earnings/?src=A00220 ...r

Looks like another eventual candidate for SC w/J&J (would be into the Hypercon timelines w/ full patient market penetration?)... https://finance.yahoo.com/healthcare/articles/warm-autoimmune-hemolytic-anemia-market-143100178.html ...imao...r

Love it. I like your theory better. Thanks for the thoughts..

No...I believe Helen is stressing the importance to the market that she is paying credence to this issue by creating this position to make sure that there are no supply disruptions if there is going to be a dramatic increase in demand for Enhanze/bulk rHuPH20 product with the forecasted revenues being presented. Add the Hypercon and Surf Bio portfolio's to the mix which cannot miss a beat as they go through their trials...Smart move since DR has most of the company's capabilities already under his belt...aimao...r

I think Halozyme just named Helens succession plan. Maybe, not sure.

Halozyme Appoints David Ramsay as President Drug DeliveryJune 30, 2026 4:02 PM
PR Newswire (US) SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026.In this newly created role, Mr. Ramsay will have an enterprise-wide, cross-technology mandate, and will be responsible for driving the growth of Halozyme's drug delivery technologies by establishing clear strategic priorities and assuring best in class business development and alliance management. David will report to Helen Torley, President and Chief Executive Officer."I am delighted to have a business leader of David's experience assume this new position at a time of unprecedented opportunity and growth for Halozyme. In his recent role as Interim Chief Financial Officer, he demonstrated his deep experience and an expansive skillset including strategic assessment, industry and partner knowledge, and, of course, deep financial expertise," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "I look forward to having David assume this newly established leadership role and contribute to the acceleration of value creation for our shareholders."Mr. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale-up.David served as Interim Chief Financial Officer of Halozyme from March 23 to June 8, 2026, until the appointment of Darren Snellgrove as Chief Financial Officer, and was responsible for leading all financial operations for the Company.He previously served as Halozyme's Chief Financial Officer from 2003 to 2009, Vice President of Corporate Development from 2009-2013 and again as Chief Financial Officer from 2013 to 2015, during which time the company evolved from a private enterprise to a billion-dollar public biopharmaceutical company. During his prior tenure as CFO, Mr. Ramsay guided the company through significant growth and played a key role in establishing Halozyme's foundational financial and technology commercialization infrastructure. Previously, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. until its sale to Allergan plc in October 2018."I am thrilled to assume this new role at Halozyme at such an important time in the Company's evolution," said Mr. Ramsay. "Halozyme's broad technology portfolio has tremendous yet untapped potential to dramatically improve the delivery of biologics for millions more patients, collaborating with industry-leading biopharmaceutical partners and resulting in new durable and growing royalty streams. I look forward to working with Helen and the entire team to drive sustainable growth and value creation for shareholders."Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley, and an M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.About HalozymeHalozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., Skye Bioscience and GSK.Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at-home and healthcare-provider settings. The addition of Surf Bio's polymer-based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx,Vertex Pharmaceuticals, and Oruka Therapeutics.Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.For more information, visit www.halozyme.com and connect with us on LinkedIn.Forward-Looking StatementsThis press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, future performance and growth of Halozyme's business. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including but not limited to unexpected levels of revenues and expenses, Halozyme's future growth (including the number of future patients using Halozyme's drug delivery technology) and shareholder value. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.Contacts: Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui @jcamp-8407
sydney.charlton@teneo.com View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-appoints-david-ramsay-as-president-drug-delivery-302815025.htmlSOURCE Halozyme Therapeutics, Inc. Original: Halozyme Appoints David Ramsay as President Drug Delivery

I would imagine that the JPM analyst will do his diligence and inquire about this on the CC w/ Helen in August...r

According to JPM, the Myositis indication could add up to $7bn in potential Vyvgart sales. Essentially, Vyvgart could become the next Darzalex for Halo. I believe ARGX's and HALO's recent strength is due to this:
"Upside from Commercial Potential remains very significant, even if only IMNM is statistically significant: Based on the CIDP dosing used in the trial and associated pricing and only treating 50% of the 20,000 IMNM patients, we estimate a $5bn opportunity for Vyvgart in IMNM alone, where we see an increased chance of success given the sizing of the IMNM part of the ALKIVIA trial. The DM opportunity would generate further upside with only 10% share of the 40,000 patients leading to a further $2bn in sales, we estimate. With every $1bn in sales worth around JPMe €40/$50 per share, we see potential for a successful result in IMNM alone de-risking a $5bn potential for Vyvgart in Myositis to drive the shares to €950/$1,100."

Argenx
Takeaways from the Myositis R&D Spotlight session

By Richard Vosser AC, Sophia Graeff Buhl Nielsen AC, Zain Ebrahim, Khushi Bihani, Dhitee Goel
Click here for the full document and disclaimers

ARGX.BR, ARGX BB
Overweight
Price (23 Jun 26):€813.00
ARGX, ARGX US
Overweight
Price (23 Jun 26):$853.40
Yesterday we attended the R&D spotlight session for Autoimmune Myositis in Boston. Here, Argenx disclosed further information regarding the subgroup patient population in the Phase II trial, where IMNM patients constituted c.60% of patients and demonstrated a statistically significant result in this subgroup alone, and DM patients (c.30% of patients) also showed a clear signal of efficacy, albeit with this subgroup not sufficiently powered to show a stat sig benefit in Phase II. Given that Phase II enrollment recruited in similar proportions to Phase III, Argenx will now analyse the primary end point for Phase III in IMNM and DM separately and file on this basis, and given a limited number of patients in PM they now no longer see a registrational path for PM. With yesterday’s session providing more insight around the potential efficacy and powering of the IMNM portion of the ALKIVIA trial, we this as further de-risking the opportunity for Vyvgart in IMNM, which we expect could be c.$5bn in itself assuming a 50% penetration of the 20k patient population. Furthermore, we continue to see a path forward for Vyvgart in DM, where despite greater heterogeneity in the patients and a small number of patients enrolled increasing the risk around whether this part of the phase III trial is sufficiently powered for a stat sig result, KOLs see the need for multiple different treatment options and the potential for combination use in this broader patient population (40k). Overall, while we expect there might be some concerns over the potential for success in DM, we see yesterday’s session as further de-risking the potential for Vyvgart in IMNM, which we estimate alone has the potential to add €150 per share to current levels, assuming success in ALKIVIA, with further upside should the DM portion of the trial also deliver a stat sig result.

Phase III analysis plan: Argenx highlighted that they are splitting up the Phase III (ALKIVIA) trial effectively into two separate trials, which they will separately seek regulatory filing for:

IMNM, which represents 60% of the 176 patients in Phase III – or c. 106 patients, which will separately be analysed for success. We assume that this will be separately analysed for statistical significance at p

You have to include Fox Business. Maria has a following larger then any of the above. Stock would rocket with her on the show. A different type of investor but one thats needed.

So a mention on CNBC’s “The Club” and one on Fast Money. Are we about to see a meaningful retail investor participation in Halo? 
Would love to see Helen on CNBC, Bloomberg, Investment Podcasts and YouTube channels! 

On June 26, 2026, Jim Cramer and Jeff Marks of the https://www.cnbc.com/investingclub/morning-meeting/ specifically highlighted Halozyme Therapeutics, pointing to its extended product revenue runway.[https://www.cnbc.com/video/2026/06/26/friday-june-26-2026-the-club-likes-this-healthcare-stock-thanks-to-its-long-product-runway.html, https://finance.yahoo.com/sectors/healthcare/articles/halozyme-therapeutics-q1-earnings-call-000901339.html]The segment centered on several bullish points driving visibility and sentiment for the biopharma company:https://www.cnbc.com/video/2026/06/26/friday-june-26-2026-the-club-likes-this-healthcare-stock-thanks-to-its-long-product-runway.html
https://www.cnbc.com/video/2026/06/26/friday-june-26-2026-the-club-likes-this-healthcare-stock-thanks-to-its-long-product-runway.html

I saw that too. Have not found anything to corroborate it.
But here us something interesting:https://www.cnbc.com/video/2026/06/29/final-trade-halo-baba-googl-spcx.html